TickerTain — Make Analysis Fun Again

▶ 3:00 · AI in Healthcare · Clinical trial automation OS cuts 12-year drug development to 6 years at half cost

episode shorts · 1

Gestionar ensayos clínicos

now playing · AI in Healthcare

AI in Healthcaretailwindscore 9/10pedro coelho

Clinical trial automation OS cuts 12-year drug development to 6 years at half cost

Biorce's AI operating system automates the clinical trial protocol lifecycle — from molecule viability simulation to protocol generation to study design optimization — reducing the median $…

AI Agentstailwindscore 8/10pedro coelho

Agentic clinical trial workforce replaces 50% of CRO human labor, targets 100% in 2 years

Biorce's 'true agentic workforce' coordinates specialized agents for protocol generation, study design, patient simulation, regulatory strategy, and economic optimization. Currently replace…

Tech Regulation & Antitrusttailwindscore 7/10pedro coelho

EU AI Act and EMA regulatory readiness become competitive moats for clinical AI

European pharma buyers require Business Continuity Plans (3-5 year runway) and auditability of AI training data flows. Biorce's single-tenant architecture with auditor-accessible training l…

AI Infrastructuretailwindscore 8/10pedro coelho

Model orchestration layer routes clinical tasks to specialized proprietary and frontier models

Biorce built a model orchestrator that decomposes clinical trial workflows into discrete tasks (protocol writing, statistical analysis, 3D molecule visualization, regulatory compliance) and…

Data Center Infrastructuretailwindscore 8/10pedro coelho

Multi-cloud single-tenant deployment with push-only model updates solves pharma data sovereignty

Biorce deploys dedicated Kubernetes clusters in each client's cloud account (AWS/Azure/GCP) with a 'data lakehouse' architecture (Databricks/Snowflake) where model updates are pushed but da…

Enterprise AI Adoptiontailwindscore 9/10pedro coelho

Pharma adopts AI clinical trial software at $250K-$10M+ ACV with 3-5 year commitments

Large pharma companies are signing multi-year contracts (70% 3-year, now piloting 5-year) for Biorce's platform at 250K-10M+ EUR base subscriptions plus usage fees. The buying trigger is re…

AI Economics & Business Modelstailwindscore 8/10pedro coelho

Hybrid subscription + usage pricing captures 10-20% of $120B CRO market value

Biorce's pricing formula (based on trial count, molecules, headcount) yields 250K-10M+ EUR base ARR per client with usage overages. At 150 trials/year for large pharma, this scales to 100M+…

Venture Capitalmixedscore 7/10pedro coelho

Deep tech fundraising requires 232 meetings for pre-seed; Series A inbound after hypergrowth proof

Biorce's pre-seed required 232 investor meetings over 5 months (12 term sheets) due to category ambiguity (SaaS vs healthtech vs biotech). Series A was inbound from Norsken/DST after 0-to-$…

←